摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-[(4-chloro-benzyl)-(1-methyl-1H-imidazole-4-sulfonyl)-amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester | 1257583-33-7

中文名称
——
中文别名
——
英文名称
6-[(4-chloro-benzyl)-(1-methyl-1H-imidazole-4-sulfonyl)-amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
英文别名
tert-butyl 6-[(4-chlorophenyl)methyl-(1-methylimidazol-4-yl)sulfonylamino]-3,4-dihydro-1H-isoquinoline-2-carboxylate
6-[(4-chloro-benzyl)-(1-methyl-1H-imidazole-4-sulfonyl)-amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester化学式
CAS
1257583-33-7
化学式
C25H29ClN4O4S
mdl
——
分子量
517.049
InChiKey
DRFGUMPKVUWKQZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    35
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    93.1
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • Compounds
    申请人:Hamlyn Richard John
    公开号:US20110136860A1
    公开(公告)日:2011-06-09
    A compound of formula (I): Or its salts or pharmaceutically acceptable derivatives thereof wherein: A represents a chemical moiety with the general formula (II): X and Y are independently selected from a group consisting of CH 2 , CH(R 5 ) or C(R 5 )(R 6 ); R 1 is selected from the group consisting of optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; R 2 is selected from the group consisting of optionally substituted aryl or optionally substituted heteroaryl or NR 7 R 8 ; R 3 R 4 R 5 R 6 R 7 and R 8 are as defined herein, n=0, 1, 2 or 3; o=0, 1 or 2, with the proviso that when o=0, then n is 1, 2 or 3 and when o=1, then n is 1 or 2 is provided. Pharmaceutical compositions comprising the compounds are also provided. These compounds are useful in the treatment of various disorders including arrhythmia.
    化合物的化学式(I):或其盐或药学上可接受的衍生物,其中:A代表具有通式(II)的化学基团:X和Y分别选自CH2、CH(R5)或C(R5)(R6)组成的一组;R1选自可选择取代的芳基烷基和可选择取代的杂环芳基烷基;R2选自可选择取代的芳基或可选择取代的杂环芳基或NR7R8;R3、R4、R5、R6、R7和R8如本文所定义;n=0、1、2或3;o=0、1或2,但当o=0时,n为1、2或3,当o=1时,n为1或2。同时还提供了包含这些化合物的药物组合物。这些化合物在治疗各种疾病,包括心律失常方面具有用途。
  • DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS
    申请人:Xention Limited
    公开号:EP2438055A1
    公开(公告)日:2012-04-11
  • US8426442B2
    申请人:——
    公开号:US8426442B2
    公开(公告)日:2013-04-23
  • [EN] DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS<br/>[FR] DERIVES DE DIHYDROINDOLE ET DE TETRAHYDROISOQUINOLINE UTILES EN TANT QU'INHIBITEURS DES CANAUX POTASSIQUES
    申请人:XENTION LTD
    公开号:WO2010139967A1
    公开(公告)日:2010-12-09
    A compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; A represents a chemical moiety with the general formula (II); X and Y are independently selected from a group consisting of CH2, CH(R5) or C(R5)(R6); R1 is selected from the group consisting of optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; R2 is selected from the group consisting of optionally substituted aryl or optionally substituted heteroaryl or NR7R8; R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, alkoxy, aryloxy, optionally substituted alkyl, optionally substituted amino, optionally substituted amino sulfonyl or nitrile; R4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfamoyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroaryl; R5 and R6 for each occurrence is optionally substituted alkyl; R7 and R8 are the same or different and each represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; n = 0, 1, 2 or 3; o = 0, 1 or 2 with the proviso that when o = 0, n is 1, 2 or 3 and when o = 1, n is 1 or 2 is provided. Pharmaceutical compositions comprising the compounds are also provided. These compounds are useful in the treatment of various disorders including arrhythmia.
查看更多